ReviewAdvances in experimental medicine and biology2025
Antifungal Innate Immunity.
Review in Advances in experimental medicine and biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite being common inhabitants of human barrier surfaces (skin, oral cavity, gut, lungs, vagina), diseases caused by fungi are rare owing to their surveillance by and sentinel function of human innate immune system. Whereas a compromised or suppressed immunity facilitates the establishment of fungal infections, the consequence of which ranges from superficial infections affecting life quality to life-threatening invasive fungal diseases. Over the last few decades, the number of people at risk for invasive fungal infections has increased due to immunosuppressive medical interventions. Also, there is an alarming increase in incidence of antifungal drug resistance, which demands alternative antifungal strategies. In vivo experimental studies have indicated that immunotherapies could be promising to combat fungal pathogens. Nevertheless, development of an effective clinical immunotherapy requires in-depth knowledge on pathobiology of fungi and the consequent host responses. Here is an overview of the defense mechanisms exerted by the human innate immune system against fungal pathogens, counteracting virulence mechanisms associated with these fungal pathogens and the innate immune system-based antifungal therapeutic strategies developed so far.
Indexed as
Identifiers
40622545What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.